Breaking News

Financial Report: Amgen

February 1, 2016

Product sales increased 3% in the quarter

Amgen
 
4Q Revenues:
$5.5 billion (+4%)

4Q Earnings: $1.8 billion (+39%)

FY Revenues: $6.9 billion (+35%)

FY Earnings: $21.7 billion (+8%)

Comments: Product sales increased 3% in the quarter, with growth driven by Enbrel (+8% to $1.4 billion), Sensipar(+21% to $384 million), Prolia (+21% to $380 million), Kyprolis (+63% to $148 million), and XGEVA (+10% to $356 million). Neulasta sales were down 2% to $1.2 billion, Neupogen sales were down 4% to $263 million, and Epogen sales were down 37% to $342 million, due to competition.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision